Technical Analysis for NBIX - Neurocrine Biosciences, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 110.44 | 1.99% | 2.15 |
Earnings due: Feb 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | 1.59% | |
Oversold Stochastic | Weakness | 1.59% | |
NR7 | Range Contraction | 1.63% | |
Narrow Range Bar | Range Contraction | 1.63% | |
Oversold Stochastic | Weakness | 1.63% | |
Outside Day | Range Expansion | 1.50% | |
Oversold Stochastic | Weakness | 1.50% | |
NR7 | Range Contraction | 1.11% | |
Narrow Range Bar | Range Contraction | 1.11% | |
Oversold Stochastic | Weakness | 1.11% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 5 hours ago |
Rose Above Previous Day's High | about 6 hours ago |
Up 1% | about 6 hours ago |
10 DMA Resistance | about 6 hours ago |
Rose Above 10 DMA | about 6 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/09/2023
Neurocrine Biosciences, Inc. Description
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Pain Alcohol Diabetes Disorders Cardiovascular Disease Schizophrenia Vascular Disease Epilepsy Hormones Ethers Movement Disorders Insomnia Transporter I Diabetes Boehringer Ingelheim Endometriosis Fibroids Ii Diabetes Essential Tremor Gnrh Antagonists Pyrimidines Uterine Fibroid Dyskinesia Gonadotropin Releasing Hormone Antagonist Neurocrine Biosciences
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 129.23 |
52 Week Low | 75.27 |
Average Volume | 716,610 |
200-Day Moving Average | 104.67 |
50-Day Moving Average | 116.94 |
20-Day Moving Average | 112.13 |
10-Day Moving Average | 108.94 |
Average True Range | 2.93 |
RSI | 37.11 |
ADX | 23.58 |
+DI | 13.50 |
-DI | 23.94 |
Chandelier Exit (Long, 3 ATRs) | 116.22 |
Chandelier Exit (Short, 3 ATRs) | 115.03 |
Upper Bollinger Bands | 122.91 |
Lower Bollinger Band | 101.34 |
Percent B (%b) | 0.32 |
BandWidth | 19.24 |
MACD Line | -2.69 |
MACD Signal Line | -2.58 |
MACD Histogram | -0.1097 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 111.02 | ||||
Resistance 3 (R3) | 111.06 | 110.19 | 110.56 | ||
Resistance 2 (R2) | 110.19 | 109.49 | 110.17 | 110.41 | |
Resistance 1 (R1) | 109.24 | 109.06 | 108.80 | 109.20 | 110.26 |
Pivot Point | 108.37 | 108.37 | 108.15 | 108.35 | 108.37 |
Support 1 (S1) | 107.42 | 107.67 | 106.99 | 107.38 | 106.32 |
Support 2 (S2) | 106.55 | 107.25 | 106.53 | 106.17 | |
Support 3 (S3) | 105.60 | 106.55 | 106.02 | ||
Support 4 (S4) | 105.56 |